Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum neurofilament light chain in multiple sclerosis: from biological signal to clinically informed decision-making.

Frontiers in neurology·2026
Same author

Modulation of the immunological and neuroinflammatory microenvironment in older people with multiple sclerosis.

Frontiers in immunology·2026
Same author

An atlas of microtubule lattice parameters regulated through ligand binding to the microtubule-stabilizing sites.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Global health security and pandemic preparedness: Europe's leadership challenge.

BMJ (Clinical research ed.)·2026
Same author

Voice recognition as an innovative method to identify and monitor heart failure - a review.

Heart failure reviews·2026
Same author

Exploring the Impact of a Heart Failure Diagnosis on Women's Lifestyles With a Specific Focus on Physical Activity, Sedentary Behaviour, Sleep, Quality of Life and Social Support.

American journal of lifestyle medicine·2026

Related Experiment Video

Updated: Jul 14, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Combination therapy in multiple sclerosis.

Oscar Fernández1

  • 1Institute of Clinical Neurosciences, Hospital Regional Universitario Carlos Haya, Málaga, Spain. fernandez.sspa.@juntadeandalucia.es

Journal of the Neurological Sciences
|May 18, 2007
PubMed
Summary

Combination therapy for multiple sclerosis (MS) may offer improved efficacy and safety over single treatments. Further large-scale clinical trials are essential to confirm these benefits for MS patients.

Area of Science:

  • Neuroimmunology
  • Neurodegenerative diseases
  • Inflammatory diseases

Background:

  • Multiple sclerosis (MS) is a complex inflammatory, demyelinating, and neurodegenerative disease.
  • Current MS treatments rely on immunomodulators or immunosuppressants, often used sequentially or escalated.
  • Monotherapies may not always achieve desired efficacy in managing MS.

Purpose of the Study:

  • To explore combination therapy as an alternative treatment strategy for multiple sclerosis.
  • To evaluate the potential for synergistic effects and reduced toxicity with combined agents.
  • To review existing evidence and ongoing research into combination therapies for MS.

Main Methods:

  • Review of existing literature on multiple sclerosis treatment strategies.

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Related Experiment Videos

Last Updated: Jul 14, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

  • Analysis of preliminary safety and efficacy data from clinical trials of combination therapies.
  • Identification of different combination approaches, including anti-inflammatory and neuroprotective agents.

    • Main Results:

    • Combination therapy in MS involves combining anti-inflammatory agents or anti-inflammatory with neuroprotective agents.
    • Preliminary studies suggest some combination therapies may be safe and efficacious for MS.
    • Many drug combinations are currently under investigation for multiple sclerosis treatment.

    Conclusions:

    • Combination therapy presents a potential alternative to monotherapy for managing multiple sclerosis.
    • Further large-scale, long-term phase III clinical trials are necessary to validate the efficacy and safety of MS combination treatments.
    • Balancing efficacy, safety, and patient information is crucial for clinical decision-making in MS treatment.